NCT01876641View on ClinicalTrials.gov

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

PHASE1TerminatedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2018

Conditions

Metastatic MelanomaMelanomaBRAF-mutated Metastatic MelanomaV600EBRAF-mutated Metastatic Melanoma

Interventions

DRUG

Vemurafenib + Cobimetinib, Decitabine

Trial Locations (1)

52242

University of Iowa Hospitals & Clinics, Iowa City

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Mohammed M Milhem

OTHER

NCT01876641 - Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | Biotech Hunter | Biotech Hunter